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INTRODUCTION
Diclofenac (DF,
) is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits potent analgesic and anti-inflammatory properties and it is widely used to treat post-operative pain, rheumatoid arthritis, osteoarthritis and acute gouty arthritis (Davies and Anderson, 1997) . When given orally, absorption is rapid and complete (Stierlin, et al., 1979; Peris-Ribera, et al., 1991; Davies and Anderson, 1997) . The metabolism of DF partitions between acyl glucuronidation and aryl hydroxylation (Tang, 2003) , and the major metabolites are DF acyl glucuronide (DF-AG), 4'hydroxy DF (4OH-DF) and 5-hydroxy DF (5OH-DF; Fig 1) . In humans, UDP-glucuronosyltransferase 2B7 (UGT2B7) catalyzes the glucuronidation of DF, whereas in rats this is Ugt2b1 (King, et al., 2001 ).
The hydroxylation of DF to 4OH-DF and 5OH-DF is catalyzed by CYP2C9 and 3A4, respectively (Tang, 2003) . After glucuronidation, DF-AG can undergo further hydroxylation (Kumar, et al., 2002) , and hydroxylated DF-AG conjugates are major urinary metabolites (Stierlin, et al., 1979) .
Extensive first-pass metabolism combined with low enterohepatic circulation reduces the oral bioavailability of DF in humans to 50-60% of the administered dose, and the metabolites of DF are predominantly eliminated in the urine (Willis, et al., 1979; John, 1979; Willis, et al., 1980) . In contrast, in rats the biliary excretion of DF glucuronides plays an important role in the elimination of DF (Peris-Ribera, et al., 1991) . Once excreted into the intestines, DF glucuronides can be hydrolyzed by bacterial β -glucuronidases, and reabsorption of DF results in significant enterohepatic circulation (Peris-Ribera, et al., 1991; . However, acyl glucuronides are chemically unstable and can undergo epimerization by acyl migration to the 2-, 3-, or 4-O-glucuronide, especially in the alkaline environment of bile, and these isomers are believed to be resistant to cleavage by bacterial β -glucuronidases (Dickinson and King, 1991; Ding, et al., 1993; Sallustio, et al., 2000; Seitz MOL #62364 extrude their substrates into bile, urine and feces, and restrict the (re)uptake of transported compounds from the gut (Schinkel and Jonker, 2003) . In contrast, MRP3 is located at the basolateral membrane of epithelial cells of kidney and intestine and at the sinusoidal membrane of hepatocytes, and pumps its substrates towards the blood circulation (Borst, et al., 2006) . DF can cause rare but serious idiosyncratic hepatotoxicity and the formation of protein adducts with reactive DF glucuronides is believed to play a role herein [reviewed in (Boelsterli, 2003; Tang, 2003) ]. Using TR¯ rats, that naturally lack Mrp2, Seitz and colleagues (1998) showed that hepatic Mrp2 mediates the efflux of DF glucuronides from the liver into the bile. Moreover, the formation of hepatic protein adducts by the reactive acyl glucuronides of DF was critically dependent on Mrp2, i.e.
TR¯ rats displayed no hepatic adducts, whereas control rats did , suggesting that Mrp2 deficiency might protect the liver from diclofenac-induced toxicity. This might explain why intra-hepatic protein adduct formation most frequently occurs in the biliary tree and not within the hepatocytes, because Mrp2 efficiently concentrates the reactive DF glucuronides in the biliary tree (Sallustio, et al., 2000) .
Furthermore, DF glucuronides, excreted into the bile by Mrp2, were shown to be involved in the formation of ulcers in the small intestine . Although DF treatment in humans also leads to the formation of gastrointestinal ulcers, DF glucuronides are predominantly exported from the human liver to the blood circulation and subsequently excreted in the urine (John, 1979; Willis, et al., 1979; Stierlin, et al., 1979) . The hepatic efflux pump(s) that is responsible for the sinusoidal transport of DF glucuronides remains to be identified. MRP3, localized in the sinusoidal membrane of hepatocytes, might be a candidate, as this transporter accepts organic anions with a preference for glucuronidated substrates .
In this study we investigated the impact of MRP2, MRP3 and BCRP on the pharmacokinetics of DF, using Mrp2
Mrp3
-/-and Bcrp1 -/-mice and all combination knockout strains. We included BCRP in this study, because we recently identified DF as a Bcrp1 substrate in vitro (Lagas, et al., 2009 ).
This article has not been copyedited and formatted. The final version may differ from this version. (Jonker, et al., 2002) , Mrp2 -/- (Vlaming, et al., 2006) , Mrp3 -/- (Zelcer, et al., 2005) , Mrp2/Bcrp1 -/- (Vlaming et al., 2009a) , Mrp2/Mrp3 -/- , Mrp3/Bcrp1 -/- (Vlaming et al., 2009b) , Mrp2/Mrp3/Bcrp1 -/- (Vlaming et al., 2009b ) and wild-type (WT) mice of a >99% FVB genetic background, between 9 and 15 weeks of age. See cited references for physiological characterization of single and combination knockout mice.
Animals were kept in a temperature-controlled environment with a 12-hour light / 12-hour dark cycle and received a standard diet (AM-II, Hope Farms, Woerden, The Netherlands) and acidified water ad libitum.
Plasma Pharmacokinetic Experiments and Tissue Distribution. For oral studies, DF (Voltaren; 25 mg/ml) was 50-fold diluted with a 5% glucose solution in water and a total volume of 10 ml/kg (5 mg/kg) body weight was administered by gavage into the stomach, using a blunt ended needle (n = 5).
To minimize variation in absorption, mice were fasted 3 hours before drug administration. Blood volume of 5 ml/kg (5 mg/kg) body weight was injected into a tail vein (n = 5). Blood samples were collected by cardiac puncture under methoxyflurane anesthesia 60 minutes after administration of the drug. Blood samples were kept on melting ice. After centrifugation at 2,100 x g for 6 min at 4°C, plasma was supplemented with 4% (v/v) of 2 M acetic acid in water and 1% (v/v) of 0.5 M ascorbic acid in water and stored at -80°C until LC-MS/MS analysis. Acetic acid and ascorbic acid were used to improve the stability of DF-AG and 5OH-DF, respectively [see (Sparidans, et al., 2008) injection of 5 mg/kg DF in a tube placed on ice, containing 10 µl 2M acetic acid and 1µl 0.5 M ascorbic acid. At the end of the experiment, blood was collected under methoxyflurane anesthesia by cardiac puncture and processed as described above. Mice were sacrificed by cervical dislocation and livers were collected en processed as described above. To determine the total biliary output of DF and metabolites, biliary excretion after dosing of 5 mg/kg DF, supplemented with [ 14 C]DF (~0.5 μ Ci per animal), was assessed in WT mice (n = 4). The levels of radioactivity were determined by liquid scintillation counting.
LC-MS/MS Analysis.
For the quantitative analysis of DF and its three principal metabolites we set up and validated a fast and sensitive LC-MS/MS method (Sparidans, et al., 2008) .
Toxicity studies. WT and Mrp2/Mrp3/Bcrp1 -/-mice were fasted overnight and i.p. injected with 5 ml/kg (25 mg/kg) body weight DF (Voltaren, 5-fold diluted with 0.9% NaCl solution to 5 mg/ml).
Blood was collected from the tail vein 3 hr after administration, using heparinized capillary tubes (Oxford Labware, St. Louis, USA). Twenty-four hr after administration, blood was collected under This article has not been copyedited and formatted. The final version may differ from this version. and Bcrp1 did not affect the oral uptake of DF, i.e. no differences in plasma concentrations were observed among all genotypes ( Fig. 2A) . In contrast, plasma concentrations of DF-AG, the main glucuronide metabolite of DF were highly increased in Mrp2 -/-and Mrp2/Bcrp1 -/-mice (Fig. 2B) .
Consequently, the area under the plasma-concentration time curve (AUC), which is a measure for the exposure to DF-AG, was 8-fold higher in Mrp2 -/-mice (2.18 ± 0.60 mg.hr/l) and 14-fold elevated in
Mrp2/Bcrp1 -/-mice (3.79 ± 1.53 mg.hr/l), when compared to WT mice (0.27 ± 0.10 mg.hr/l; Fig. 1B , insert). Furthermore, Mrp2/Bcrp1 -/-mice had significantly higher DF-AG plasma concentrations than
Mrp2
-/-mice at 2 and 4 hr after oral administration, although the AUC 0-6 was not significantly different between these genotypes (P = 0.06; Fig. 2B ). Deficiency of Mrp2 thus seems the main cause of the highly increased DF-AG plasma concentrations. The maximal plasma concentrations of DF as well as DF-AG were probably reached before the first sampling time point, i.e.15 min after oral administration ( Fig. 2A and 2B ), testifying to the rapid kinetics of these compounds.
Biliary excretion of DF and DF-AG in Mrp2
-/-, Bcrp1 -/-and Mrp2/Bcrp1 -/-mice. As the metabolic conversion of DF predominantly occurs in the liver (Vargas and Franklin, 1997) mice, i.e., elevated liver but not plasma levels of DF-AG ( Fig. 3D and 3F ). We will return to this difference in the discussion. Furthermore, the fact that biliary output of DF-AG was not completely abrogated in Mrp2/Bcrp1 -/-mice points towards additional efflux mechanism(s) for DF-AG in the canalicular membrane, other than Mrp2 and Bcrp1. Nonetheless, the lower biliary excretion of DF-AG in Mrp2/Bcrp1 -/-mice was associated with both markedly increased liver concentrations (Fig. 3D) and higher plasma concentrations (Fig. 3F ).
Biliary excretion of 4OH-DF and 5OH-DF in Mrp2
-/-, Bcrp1 -/-and Mrp2/Bcrp1 -/-mice. The levels of the two principal hydroxylated metabolites of DF, 4OH-DF and 5OH-DF (Fig. 1) , were also measured in plasma, bile and liver (Table 1) . Interestingly, although liver and plasma levels of these metabolites were not significantly different, the biliary output of 4OH-DF was 17.3-and 19.2-fold (i.e., by 94% and 95%) decreased in Mrp2 -/-and Mrp2/Bcrp1 -/-mice, respectively (P < 0.01; Table 1 ).
Furthermore, the excretion of 5OH-DF in the bile was 2.4-and 3.2-fold (i.e., 58% and 69%) lower in
Mrp2
-/-and Mrp2/Bcrp1 -/-mice, respectively (P < 0.05; Table 1 ). In single Bcrp1 -/-mice, the biliary excretion of these metabolites was not different from WT mice. The biliary output of these hydroxylated DF metabolites, particularly of 4OH-DF, thus seems to depend largely on Mrp2.
However, the impact of this process on liver and plasma levels of these metabolites was negligible, in line with the modest amounts excreted into bile. . As depicted in Table 1 , the biliary excretion of DF and DF-AG in WT mice was 0.04 and 4.2% of the dose, respectively. In addition, the excretion of 4OH-DF and 5OH-DF into the This article has not been copyedited and formatted. The final version may differ from this version. bile accounted for 0.14 and 0.053% of the dose, respectively (Table 1) . Together, DF and its primary metabolites therefore represent only ~10% of the 14 C-label excreted into bile. The majority of the radioactivity in the bile must thus originate from DF metabolites other than DF-AG, 4OH-DF or 5OH-DF. When analyzed with LC-MS/MS, we indeed observed additional peaks in the chromatograms of the bile samples. Based on mass, retention time, and fragmentation patterns, 4OH-DF-AG and 5OH-DF-AG could be identified. Another peak represented isomer(s) of DF-AG, which originated from epimerization of the 1-O-glucuronide by acyl migration to 2-, 3-or 4-O-glucuronide Sallustio, et al., 2000) . Acyl migration especially occurs at alkaline pH, and since mouse bile has a pH of ~9, it is likely that a significant amount of the DF-AG was converted to isomeric isoforms before we could stabilize the compound with acetic acid. As we do not have reference standards for these compounds, these metabolites could not be quantified and therefore their biliary output is given in arbitrary units, normalized to the output in WT bile (Fig. 4) . By and large, the excretion patterns of 4OH-DF-AG, 5OH-DF-AG and the isomer(s) of DF-AG were qualitatively similar to that of DF-AG, indicating that biliary excretion of these glucuronide metabolites was predominantly mediated by Mrp2 and Bcrp1.
Biliary excretion of DF glucuronide metabolites other than DF-AG in
Basolateral efflux of DF-AG in the liver is mediated by Mrp3. In the liver, Mrp3 is expressed at the sinusoidal (basolateral) membranes of hepatocytes and it transports its substrates towards the blood circulation. Because Mrp3 is a typical organic anion transporter with a preference for glucuronidated substrates [reviewed in (Fig. 5B) . Accordingly, the DF-AG concentrations in the liver, determined at 60 minutes after administration, were ~1.8-fold elevated in Bcrp1 -/-and Mrp2/Bcrp1 -/-mice, and 3.3-fold in Mrp2/Mrp3/Bcrp1 -/-mice (Fig. 5D) . Interestingly, in the livers of Mrp2/Mrp3/Bcrp1 -/-mice, but not in WT livers, also substantial accumulation of 4OH-DF-AG, 5OH-DF-AG and of DF-AG isomers was observed (not shown). As mentioned above, the lack of reference compounds made it impossible to quantify these metabolites. However, as DF acyl glucuronide metabolites are associated with idiosyncratic hepatotoxicity [reviewed in (Tang, 2003; Boelsterli, 2003)] we hypothesized that Mrp2/Mrp3/Bcrp1 -/-mice might be more prone to DF-induced liver toxicity than WT mice.
Mrp2/Mrp3/Bcrp1 -/-mice develop mild DF-induced acute hepatotoxicity. To test whether
Mrp2/Mrp3/Bcrp1 -/-mice were more sensitive to DF-induced liver toxicity, DF was i.p. administered at 25 mg/kg to WT and Mrp2/Mrp3/Bcrp1 -/-mice (n = 4) and ALAT and alkaline phosphatase levels in plasma were determined 3 and 24 hr after administration. In addition, livers were isolated 24 hr after administration and examined for histological signs of toxicity. Both WT and Mrp2/Mrp3/Bcrp1 -/-mice that were treated with DF did not display changes in plasma alkaline phosphatase or histological signs of hepatotoxicity (data not shown). Furthermore, ALAT levels in WT mice were not altered after treatment with DF. However, treatment of Mrp2/Mrp3/Bcrp1 -/-mice with DF resulted in significantly higher (~2-fold, P < 0.05) ALAT levels at both time points (Fig. 6 ), suggesting that these mice displayed acute, albeit very mild, liver toxicity.
This article has not been copyedited and formatted. The final version may differ from this version. (Vlaming, et al., 2006; Vlaming, et al., 2009a; Vlaming, et al., 2009b) . This makes it unlikely that alterations in expression of these transporters could substantially affect the interpretation of our data.
We recently demonstrated that mouse Bcrp1 can transport DF in vitro (Lagas, et al., 2009 ). In the present study, however, loss of Bcrp1 in mice did not affect the oral uptake or biliary excretion of DF.
On the other hand, deficiencies in Bcrp1 and Mrp2 resulted in impaired biliary output of DF glucuronides. In addition to glucuronides, we also found that Mrp2, but not Bcrp1, mediates the biliary excretion of the hydroxylated DF metabolites, 4OH-DF and 5OH-DF.
From studies in rats, Mrp2 was already known to mediate the biliary excretion of DF glucuronides . Moreover, hepatobiliary excretion of DF glucuronides in TR¯ rats, a spontaneous mutant lacking Mrp2, is almost completely abrogated . In contrast, in mice we show that the biliary excretion of DF glucuronides is mainly dependent on both Mrp2 and Bcrp1. This species difference is in line with previous findings showing that the biliary excretion of 4-methylumbelliferyl glucuronide in rats is primarily mediated by Mrp2, whereas in mice both Mrp2 and Bcrp1 play a role in this process (Zamek-Gliszczynski, et al., 2006a; Zamek-Gliszczynski, et al., 2006b) . Our observation that the biliary output of DF-AG was not This article has not been copyedited and formatted. The final version may differ from this version. Figs 3D and 5D ) and, as a consequence, highly increased plasma concentrations of DF-AG ( Figs 2B, 3F and 5B).
Notably, after oral DF administration, maximal plasma concentrations of DF-AG are reached within 15 minutes after administration (Fig 2B) . This might suggest that the glucuronidation of DF already occurs in the gastrointestinal tract, as the gut, in addition to the liver, is an important organ for glucuronidation (Tukey and Strassburg, 2000) . However, studies in rats demonstrate that DF is predominantly glucuronidated in the liver and not in the gut (Ware, et al., 1998; Vargas and Franklin, 1997; . The glucuronidation of DF in rats is catalyzed by Ugt2b1 (King, et al., 2001 ) and since rat and mouse Ugt2b1 proteins share >85% homology (www.ensembl.org), murine Ugt2b1 may also be primarily responsible for the glucuronidation of DF. In rats and mice, the liver is the predominant tissue for the expression of Ugt2b1, whereas expression in the intestine is low (Shelby, et al., 2003; Buckley and Klaassen, 2007) . We find that approximately 40% of an i.v. dose of DF is excreted as glucuronide metabolites in the bile of WT mice within 60 minutes, indicating that the liver indeed is the major tissue for DF glucuronidation in mice. We therefore believe that the early C max of DF-AG (Fig. 2B ) may be explained by very fast oral absorption of DF ( Fig. 2A) , enabling rapid hepatic uptake and subsequent conversion to DF-AG. The fact that DF was given as an aqueous solution in combination with temporary food deprivation before administration may explain the rapid absorption of the drug. Indeed, in humans the T max of an aqueous DF solution was reached in 10-30 min, whereas this was ~2 hr for a tablet with the same DF dose (John, 1979 ).
Mrp3 has a preference for glucuronidated compounds and plays a dominant role in the transport of glucuronides across the sinusoidal membrane of hepatocytes (reviewed in . Our results suggest that Mrp3 also predominantly mediates the transport of DF-AG from the liver toward the blood circulation. Interestingly, in humans DF acyl glucuronides are predominantly excreted from the liver to the blood circulation and subsequently excreted in the urine (John, 1979; Willis, et al., 1979; Stierlin, et al., 1979) . This could mean that MRP3 in the sinusoidal membrane of human hepatocytes has a higher affinity for DF acyl glucuronides than canalicular MRP2, whereas in mice This article has not been copyedited and formatted. The final version may differ from this version. (Vlaming, et al., 2006; Vlaming, et al., 2009a) . This likely explains why, although the biliary DF-AG excretion is impaired in Mrp2 -/-and Mrp2/Bcrp1 -/-mice, substantial hepatic accumulation of DF-AG is not observed (Fig. 5D ) and that plasma concentrations of DF-AG are highly elevated in Mrp2 -/-and Mrp2/Bcrp1 -/-mice ( Figs 2B, 3F and 5B). In contrast, in Bcrp1 -/-mice, which do not have altered Mrp3 expression in their liver (Vlaming, et al., 2009a) , impaired biliary excretion of DF-AG results in liver accumulation without elevated plasma concentration ( Figs   3D and 3F ).
The 24-fold increased plasma level of DF-AG in Mrp2/Bcrp1 -/-mice ( Fig. 5B ) was restored to WT levels in Mrp2/Mrp3/Bcrp1 -/-mice. We therefore had expected that DF-AG would be highly accumulated in the livers of in Mrp2/Mrp3/Bcrp1 -/-mice, but hepatic levels of DF-AG in this strain were only 3.3-fold higher than in WT mice (Fig. 5D ). The relatively low DF-AG accumulation in
Mrp2/Mrp3/Bcrp1 -/-mice might partially be explained by the fact that biliary excretion of DF-AG in
Mrp2/Bcrp1
-/-mice is not completely abrogated, but reduced by ~75% (Fig. 3B ). There must thus be other canalicular efflux system(s) for DF-AG, possibly with low affinity and high capacity. However, subsequent hydroxylation of DF-AG and/or acyl migration of DF-AG in the liver may also contribute to the relatively low DF-AG concentration in the liver of Mrp2/Mrp3/Bcrp1 -/-mice. Indeed, DF-AG can undergo further hydroxylation in the liver (Kumar, et al., 2002) . In fact, in rats the biliary excretion of metabolites that were hydroxylated and glucuronidated was approximately equal to that of DF-AG . Furthermore, substantial acyl migration has been observed in vivo as well (Sallustio, et al., 2000; Boelsterli, 2003) . Our results suggest that the majority of radioactivity in the bile of WT mice can be attributed to 4OH-DF-AG, 5OH-DF-AG and DF-AG isomer(s). Unfortunately, these metabolites could not be quantified, but their biliary efflux was largely dependent on Mrp2 and Bcrp1 (Fig. 4) non-enzymatic reactions (Sallustio, et al., 2000) . Hepatic protein adducts of DF acyl glucuronides, including hydroxylated DF-AG metabolites and DF-AG isomers, are believed to play an important role in DF-induced idiosyncratic hepatotoxicity [reviewed in (Boelsterli, 2003; Tang, 2003) In humans, the rare idiosyncratic hepatotoxicity that can be induced by DF is characterized by a delayed onset of symptoms and usually occurs between 1 and 6 months after starting the treatment (Boelsterli, 2003; Tang, 2003) . There are many indications that, in addition to hepatic adduct formation by reactive metabolites, other factors, including immune-mediated responses, contribute to the liver toxicity (Boelsterli, 2003; Tang, 2003) . Our results suggest some acute but mild liver toxicity in Mrp2/Mrp3/Bcrp1 -/-mice, and although it was beyond the scope of this study, it might be interesting to investigate this toxicity in more detail or in a much longer time frame in these transporter-deficient mouse models.
In conclusion, our results show that Mrp2, Mrp3 and Bcrp1 play an important role in the distribution and elimination of DF acyl glucuronides in mice, both after oral and intravenous administration. We expect that acyl glucuronide metabolites of many more drugs will be similarly affected by these ABC transporters. , Bcrp1 -/-and Mrp2/Bcrp1 -/-mice. After ligation of the common bile duct and cannulation of the gall bladder DF (5 mg/kg) was given i.v. followed by bile collection for 60 min and tissue isolation and plasma collection at 60 min. Data represent means ± SD (n = 5 per strain).
* P < 0.05, ** P < 0.01 and *** P < 0.001, compared to WT mice. # P < 0.05 and ## P < 0.01, compared to Mrp2 -/-mice. † P < 0.05 and † † P < 0.01, compared to Bcrp1 -/-mice. given i.v. followed by plasma collection and tissue isolation at 60 min. Data represent means ± SD (n = 5 per strain). * P < 0.05, ** P < 0.01 and *** P < 0.001, compared to WT mice. ## P < 0.01, compared to Mrp2 -/-mice. Mice were i.p. injected with vehicle (V) or DF (25 mg/kg) and blood was collected 3 hr and 24 hr after administration. Data represent means ± SD (n = 4 per strain). * P < 0.05 and ** P < 0.01, compared to WT mice receiving vehicle.
This article has not been copyedited and formatted. The final version may differ from this version. 
